home / stock / dskyf / dskyf news


DSKYF News and Press, Daiichi Sankyo Co Ltd

Stock Information

Company Name: Daiichi Sankyo Co Ltd
Stock Symbol: DSKYF
Market: OTC

Menu

DSKYF DSKYF Quote DSKYF Short DSKYF News DSKYF Articles DSKYF Message Board
Get DSKYF Alerts

News, Short Squeeze, Breakout and More Instantly...

DSKYF - ASCO Annual Meeting 2024: Breakthrough Treatments Hint At Renewed Hope For Patients And Investors

2024-07-17 04:42:00 ET Summary As medical companies leverage the power of artificial intelligence, genomics, and other groundbreaking discoveries, the boundaries between technology and healthcare continue to blur, presenting potential opportunities for both patients and investors. ...

DSKYF - How To Pick Top Pharma Stocks: Novo Nordisk And More

2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...

DSKYF - Merck, Daiichi lung cancer therapy rejected in U.S.

2024-06-27 07:56:32 ET More on Merck Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Tran...

DSKYF - Pfizer: Seriously Undervalued At Peak Pessimism

2024-06-23 11:13:33 ET Summary Since the publication of my last article, Pfizer has continued to surprise me pleasantly. In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street. On June 14, 2024, the c...

DSKYF - Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue

2024-06-12 03:27:58 ET Summary Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the primary revenue driver today, has shown promising r...

DSKYF - AstraZeneca reports positive data for Tagrisso, Imfinzi, Enhertu

2024-06-03 12:43:22 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market Emerging and Chinese pharmas playing grea...

DSKYF - AstraZeneca, Daiichi Sankyo ADC misses key endpoint in phase 3 lung cancer trial

2024-05-28 12:29:50 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market Nona Biosciences and AstraZeneca sign glo...

DSKYF - Novo Nordisk, J&J lead R&D rankings in big pharma: report

2024-05-18 14:52:07 ET More on GSK, Johnson & Johnson, etc. Shockwave Medical: A Look Into Q1 Financials And Value To Johnson & Johnson Investors Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Johnson & Johnson (JNJ) ...

DSKYF - ClearBridge Global Growth Strategy Q1 2024 Portfolio Manager Commentary

2024-04-26 12:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...

DSKYF - Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript

2024-04-25 23:50:27 ET Daiichi Sankyo Company, Limited (DSKYF) Q4 2023 Earnings Call Transcript April 25, 2024 02:00 AM ET Company Participants Kentaro Asakura - VP of Corporate Communications Department Hiroyuki Okuzawa - Representative Director, President and COO ...

Next 10